Academic cancer centers are facing severe staffing shortages after three years of personnel attrition during the COVID-19 pandemic—resulting in depressed levels of patient accrual to investigator-initiated and grant-funded clinical trials.
The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.
